Click for Study

Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab

Sponsor: Merck/Cedars-Sinai
Protocol Number: 2018-04-McArthur-neoHP
Start Date: 11/15/2019
Active, projected trial end date 10/2024